On 27 October 2006, orphan designation (EU/3/06/409) was granted by the European Commission to Erytech Pharma S.A., France, for L-asparaginase encapsulated in erythrocytes for the treatment of acute lymphoblastic leukaemia.
L-asparaginase encapsulated in erythrocytes
Treatment of acute lymphoblastic leukaemia
|Orphan designation status||
|EU designation number||
|Date of designation||
Erytech Pharma S.A.
60, avenue Rockefeller
Telephone: +33 4 78 74 44 38
Telefax: +33 4 78 75 56 29
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: